Effectiveness of antenatal dexamethasone in reducing respiratory distress syndrome and mortality in preterm neonates: a nested case control study

Preterm delivery, defined as delivery before completion of 37 weeks of gestation, is the leading cause of perinatal and neonatal mortality and morbidity [1]. Preterm birth is a global problem; however, 81% of all preterm births occur in Asia and sub-Saharan Africa [2]. Due to their immaturity, preterm infants are vulnerable to several complications such as feeding difficulties, impaired thermoregulation, short and long term neurological problems.

Respiratory distress syndrome (RDS), also known as hyaline membrane disease, is a breathing disorder commonly affecting premature infants because their lungs are not able to make enough surfactant [3]. Factors like infections and smoking during pregnancy, gestational diabetes, type of delivery and stress during delivery increase the likelihood of RDS in newborns [4]. Several measures are in place to improve newborn outcomes in the settings of premature delivery, including the administration of antenatal corticosteroids (ACS).

The World Health Organisation (WHO) recommends using either dexamethasone or betamethasone for women at risk of preterm birth from 24 to 34 weeks of gestation when preterm birth is considered imminent, with no clinical evidence of maternal infection and adequate childbirth care is available [5, 6]. An optimum time of delivery from corticosteroid administration is 2 to 7 days. A single repeat course of ACS is recommended if preterm birth does not occur within 7 days after the initial dose, and a subsequent clinical assessment demonstrates a high risk of preterm birth in the next 7 days [5].

In Tanzania, prematurity and its complications are among the leading causes of death among neonates [7]. Since 2015, dexamethasone has been widely available to the district hospital level following the preparation of national guidelines for ACS use and their addition to the national essential medicine list. However, there have been a slow decline in neonatal mortality from 22.1 deaths per 1000 live birth in 2015 to 20.3 deaths per 1000 live births in 2019 [8]. Tanzania has limited facilities that can manage preterm neonates with any respiratory distress since the capacity to deliver continuous positive airway pressure (CPAP), intubate and administer surfactant as indicated is inadequate [9].

The Cochrane meta-analysis of 2017 that forms a basis of WHO recommendations; included 29 trials conducted in high resource countries with standard neonatal care [10]. Another review on the impact of ACS in low and middle-income countries had inconclusive findings because some studies in such settings reported no benefit of ACS in reducing neonatal mortality and RDS [11]. The ACTION trial that included a total of 2852 women (and their 3070 fetuses) across tertiary hospitals in Bangladesh, India, Kenya, Nigeria, and Pakistan who were at risk for early preterm birth reported that the use of dexamethasone resulted in significantly lower risks of neonatal death alone and stillbirth or neonatal death than the use of placebo, without an increase in the incidence of possible maternal bacterial infection [12]. Thus, there is a need for more evidenceon the benefit of ACS use in low resource settings where pregnant women start antenatal visits late together with inadequate number of neonatal care facilities.

This study, therefore, aimed at assessing the effectiveness of ACS in reducing RDS and neonatal mortality in preterm neonates in resource-limited settings.

This study found no association between ACS use and RDS occurrence. This is contrary to other studies for example a study conducted in Brazil whereby RDS incidence was reduced with antenatal corticosteroid use [17]. Differences in the epidemiology of preterm birth, exposure to infections, pharmacogenetical factors and quality of neonatal care could be the likely reasons for the observed differences.

Gestational age at delivery and neonatal birth weight were found to be independent predictors of RDS in preterm neonates. Hereby, a complete week increase in gestational age at delivery is associated with a 19% decrease in the odds of developing RDS where as a gram increase in neonatal birth weight is associated with a 0.2% reduction in RDS odds. There is a direct relationship between gestational age at delivery and neonatal birth weight [18]. These two are directly related to RDS occurrence because the latter happens as a result of immature lungs with inadequate surfactant. Surfactant production in the fetus mostly occurs after 30 weeks of gestation. Thus, neonates born prior to this age are likely to suffer from RDS [19]. These findings are similar to a study conducted in the neonatal unit in Cameroon to assess the prevalence, predictors and outcomes of neonatal distress [20]. Several other studies have reported gestational age and neonatal birth weight as predictors of RDS in preterm neonates [21, 22]. Also, in this study, 1 min Apgar score of less than 7 was found to be an independent predictor of RDS in preterm neonates. Hereby preterm neonates who scored less than 7 at one minute were three times more likely to develop RDS compared to those with an APGAR score of more than 7. This finding is similar to the findings of a prospective study in Ethiopia that showed an APGAR score less than 7 (AHR: 3.1 (95%CI: 1.8–5.0) to be a significant predictor of RDS in preterm neonates [23]. Apgar score is used as a quick assessment tool of neonates immediately after birth. Therefore, neonates with immature lungs might struggle to initiate and maintain spontaneous respiration after birth.

This study found an overall mortality rate of 9 per 1000 preterm neonates. Death was reported in 23 (6.97%) of the preterm neonates. In this study, not receiving ACS, low birth weights, RDS, low APGAR scores and prematurity have been associated with increased mortality rates. This could be due to the fact that preterm newborns are at greater risk of death, which could result from physical and physiologic immaturities [24]. These findings are consistent with other studies and reports in sub Saharan Africa [25]. This can be because many countries in this region do not have enough facilities in terms of expertise and equipment that are capable of providing adequate care to neonates with respiratory problems and those who suffered from intrapartum hypoxia. However, contrary to our study, maternal comorbidities were associated with increased neonatal mortality rates [25]. In our study neonates delivered by mothers with non-communicable comorbidities had the lowest mortality rates (8 per 1000 neonates) compared to those whose mothers had no comorbidities. This could be because mothers with comorbidities are more likely to receive preventive care as the likelihood of preterm delivery is expected compared to those without.

Another study conducted at a neonatal unit in northern Tanzania on cause of specific neonatal mortality documented that prematurity was the second leading single cause of neonatal deaths especially in low birth weight neonates (94.7%), whereby case fatality declined with increasing birth weight [26]. This is similar to our findings whereby more deaths occurred in the extremely low birth weight neonates and no deaths occurred in normal birth weight ones. Several other studies conducted in Tanzania report similar findings [27, 28].

In our study fewer deaths occurred in the neonates exposed to antenatal dexamethasone (2.5%) compared to those unexposed to antenatal dexamethasone (11%). Although antenatal dexamethasone decreased incidence of neonatal mortality, there was no significant association upon multivariate analysis. These findings are consistent with several other studies that have shown fewer deaths with dexamethasone use [17, 29, 30]. These findings are also consistent with those reported by the ACTION trial that included a total of 2852 women (and their 3070 fetuses) across tertiary hospitals in low and middle income countries who were at risk for early preterm birth whereby the use of dexamethasone resulted in significantly lower risks of neonatal death alone and stillbirth or neonatal death than the use of placebo, without an increase in the incidence of possible maternal bacterial infection [12]. However, these findings are contrary to the antenatal corticosteroid trial (ACT trial) done in low resource settings, which found an overall increase in 28-day neonatal mortality and stillbirth associated with the intervention[31], and a study in a rural Tanzanian hospital, which found poor neonatal outcomes associated with antenatal corticosteroid use [32]. This could be because our study was conducted in a tertiary and referral hospital which have the required facilities and expertise to care for preterm neonates.

In this study, majority of the deaths occurred in neonates delivered at 28 to 32 gestational weeks (14.4%). Similar to our findings, a multicenter hospital-based investigation of preterm neonatal mortality in China found most of the deaths (57.9%) occurred in neonates delivered at 28 to 32 weeks of gestation [33]. A unit increase in gestational age was independently associated with a 30% reduction in neonatal mortality risk, according to our findings. Furthermore, in this study, spontaneous vaginal delivery had higher mortality rates compared to caesarean section. These findings are consistent to a study conducted in the US on very preterm infants, comparing the mortality rates between neonates delivered by primary spontaneous vaginal delivery and caesarean section. The study found that caesarean section significantly reduced the risk of neonatal death among the very preterm neonates (adjusted odds ratios of 0.58, 0.52, 0.72, and 0.81 for 22, 23, 24, and 25 weeks, respectively) [34]. However, contrary to our findings, a review on trends in neonatal, post-neonatal, infant, child and under-five mortalities in Tanzania from 2004 to 2016 showed that neonates delivered by caesarean section had a higher risk of mortality compared to vaginal delivery [35]. This can be because the study was conducted in referral hospitals with enough resources and well-trained personnel.

Increase in gestational age was found to be protective against neonatal mortality and RDS. One minute APGAR score of < 7 and low neonatal birth weights are predictors of RDS in preterm neonates. ACS was not associated with reduced neonatal mortality rates and RDS occurrence in preterm neonates. Larger prospective studies should be conducted to determine the exact preconditions of antenatal corticosteroid therapy in low-resource settings.